3,4 . Arrestins also function as ligand-regulated scaffolds that recruit multiple non-G-protein effectors into GPCR-based 'signalsomes' 5,6 . Although the dominant function(s) of arrestins vary between receptors, the mechanism whereby different GPCRs specify these divergent functions is unclear. Using a panel of intramolecular fluorescein arsenical hairpin (FlAsH) bioluminescence resonance energy transfer (BRET) reporters 7 to monitor conformational changes in β-arrestin2, here we show that GPCRs impose distinctive arrestin 'conformational signatures' that reflect the stability of the receptor-arrestin complex and role of β-arrestin2 in activating or dampening downstream signalling events. The predictive value of these signatures extends to structurally distinct ligands activating the same GPCR, such that the innate properties of the ligand are reflected as changes in β-arrestin2 conformation. Our findings demonstrate that information about ligand-receptor conformation is encoded within the population average β-arrestin2 conformation, and provide insight into how different GPCRs can use a common effector for different purposes. This approach may have application in the characterization and development of functionally selective GPCR ligands 8,9 and in identifying factors that dictate arrestin conformation and function.
BRET signals comparable to unmodified rLuc-β-arrestin2. The sixth construct (F3), which was poorly recruited, was included in subsequent experiments as an internal negative control. We then tested whether GPCR activation would produce an intramolecular rLuc-β-arrestin2-FlAsH BRET signal upon recruitment to an untagged GPCR. Agonist stimulation elicited changes in the β-arrestin2-FlAsH BRET signal (Δnet BRET) that were maintained over at least 10 min (Extended Data Fig. 1a ) and proportional to receptor occupancy at less than saturating ligand concentration (Extended Data Fig. 1b ). Thus, measuring the Δnet BRET of each construct produced a β-arrestin2-FlAsH BRET signature that was characteristic of the receptor being investigated (Fig. 1c ). For the vasopressin type 2 receptor (V 2 R), ligand stimulation caused significant decreases in the signal from FlAsH sensors in the N-terminal (F1 and F2) and C-terminal (F4 and F5) globular domains, and a significant increase in signal from the sensor located at the C terminus (F6). Predictably, given its poor recruitment, the F3 construct did not significantly change with stimulation.
To determine whether β-arrestin2-FlAsH signatures were conserved between GPCRs, we selected a panel of six additional receptors with diverse G-protein coupling, arrestin binding, and arrestin-dependent signalling characteristics (Extended Data Table 1 ). Our test panel included two stable arrestin-binding class 'B' 17 GPCRs: the angiotensin AT 1A receptor (AT 1A R) and the type 1 parathyroid hormone receptor (PTH 1 R); three transient arrestin-binding class ' A' 17 GPCRs: the α 1B -adrenergic receptor (α 1B AR), the β 2 -adrenergic receptor (β 2 AR), and the sphingosine-1-phosphate 1 receptor (S1P 1 R); and the α 2Aadrenergic receptor (α 2A AR) that does not produce detectable β-arrestin2 translocation. The G-protein-mediated signalling of each receptor was characterized using a FLIPR TETRA fluorescent imaging plate reader to measure ligand-dependent activation or inhibition of adenylyl cyclase and stimulation of transmembrane Ca 2+ entry 18 (Extended Data Fig. 2 ). The pattern of arrestin recruitment was confirmed by confocal fluorescence microscopy using GFP-tagged β-arrestin2 (ref. 19) ( Fig. 2a ). The β-arrestin2-FlAsH BRET signature generated by each receptor is shown in Fig. 2b . As the Δnet BRET observed with each probe reflects the 'population average' conformation of the cellular pool of rLuc-β-arrestin2-FlAsH, signatures were generated under conditions of receptor excess and saturating ligand concentration to ensure that the largest possible fraction of the reporter pool was receptor-bound at steady state. Inspection of the rLuc-β-arrestin2-FlAsH BRET signatures revealed that the class B receptors AT 1A R, PTH 1 R and V 2 R ( Fig. 1c ), which form stable GPCR-arrestin complexes that transit to endosomes 17 , produced significant negative Δnet BRET signals at the F4 position and positive Δnet BRET signals at the C terminus ( Fig. 2b ; black arrows). In contrast, the class A α 1B AR, β 2 AR and S1P 1 R, which dissociate from arrestin soon after internalization 17 , produced little to no signal in these positions. Only small N-terminal responses were observed with α 2A AR, which interacts weakly with β-arrestin2 (ref. 20) .
LETTER RESEARCH
To relate the β-arrestin2-FlAsH BRET signature to arrestindependent signalling, we determined the effect of silencing β-arrestin1/2 expression on ligand-stimulated ERK1/2 activation 21,22 using HEK293 FRT/TO β-arrestin1/2 shRNA cells that carry tetracycline-inducible shRNA targeting β-arrestin1/2 (ref. 23) . As shown in Fig. 2c , ERK1/2 activation by AT 1A R, PTH 1 R and α 1B AR was significantly attenuated by β-arrestin1/2 silencing, indicating a positive signalling role for arrestin scaffolds 24 . β-arrestin1/2 silencing had no net effect on ERK1/2 activation by β 2 AR, which reportedly activates ERK1/2 via both G i/o -dependent and arrestin-dependent pathways in HEK293 cells 25 , and significantly enhanced ERK1/2 activation by the S1P 1 R and α 2A AR, suggesting that for these receptors the major role of arrestins is to dampen G-protein-dependent ERK1/2 activation by promoting desensitization. Consistent with this, we found that ERK1/2 activation via β 2 AR, S1P 1 R and α 2A AR was strongly pertussis toxin-sensitive, indicating a predominantly G i/o -mediated mechanism of activation (Extended Data Fig. 3 ). Comparison with the rLuc-β-arrestin2-FlAsH BRET signatures revealed a correlation between arrestin-dependent ERK1/2 activation and a significant negative Δnet BRET signal at the F5 position. This was most apparent for the class A α 1B AR, which lacked the F4 and F6 signals characteristic of class B receptors, but retained the F5 signal shared by GPCRs mediating arrestin-dependent signals ( Fig. 2b ; grey arrows). The relationship between α 1B AR-induced F5 signal and ERK1/2 activation was present over a range of agonist concentrations (Extended Data Fig. 4a ), whereas at saturating ligand concentration the F5 signal readily separated the positive and negative roles of arrestin in ERK1/2 activation by our panel of seven GPCRs (Extended Data Fig. 4b ).
We next examined chimaeric GPCRs in which the receptor C-tail was exchanged to reverse the class A and class B patterns of arrestin binding. As shown in Fig. 3a , replacing the C-tail of the class B V 2 R with that of the class A β 2 AR (V 2 β 2 ctR) is sufficient to reverse the arrestin binding pattern 26 . Although the C-tail exchange affected the stability of the receptor-arrestin complex, it did not affect arrestin-dependent ERK1/2 activation, which persisted in the V 2 β 2 ctR. Comparison of the rLuc-β-arrestin2-FlAsH BRET profiles generated by V 2 R and V 2 β 2 ctR revealed that conversion of class B to class A binding caused the loss of the negative F4 signal characteristic of class B receptors such as AT 1A R, PTH 1 R, and V 2 R (Fig. 2b) . In contrast, the F5 signal was preserved, such that the rLuc-β-arrestin2-FlAsH BRET signature of the chimaeric V 2 β 2 ctR resembled that of the α 1B AR, the other class A GPCR that retained arrestin signalling. The opposite experiment, involving conversion of a class A receptor to class B, is shown in Fig. 3b . Replacing the C-tail of the class A β 2 AR with that of the class B V 2 R (β 2 V 2 ctR) reverses the arrestin binding pattern. In this case, β 2 V 2 ctR-mediated ERK1/2 activation became more arrestin-dependent, as evidenced by acquired sensitivity to shRNA silencing of β-arrestin1/2 expression. Inspection of the β-arrestin2-FlAsH BRET profiles of β 2 R and V 2 β 2 ctR revealed that conversion of class A to class B produced a significant increase in the F4 signal that was most apparent following 10 min of ligand stimulation. Notably, the F5 signal also increased, consistent with the gain of arrestin-dependent signalling. Thus, reversing the stability of the arrestin-GPCR complex, without altering the other intracellular loops of the receptor, was sufficient to produce loss/gain of FlAsH BRET signal at the F4 position, whereas the magnitude of change in the F5 position correlated with arrestin-dependent signalling.
We then compared the β-arrestin2-FlAsH BRET signature generated by angiotensin II (AngII) with those of a previously characterized series of arrestin-selective 'biased' AngII analogues 27 (Fig. 3c) 
ligands promote arrestin-dependent ERK1/2 activation corresponds to the avidity of the complex, with longer half-life complexes generating proportionally greater arrestin-dependent signalling 27 . Inspection of the β-arrestin2-FlAsH BRET signatures demonstrated that although different ligands had little effect on the magnitude of the N-terminal F1 shift, the amplitude of the F4 and F5 signals were very sensitive to ligand structure. Plotting the F4 signal versus receptor-arrestin avidity measured by FRAP revealed a strong linear correlation. Thus, the signature presented by β-arrestin2-FlAsH BRET probes in the C-terminal domain reflected the avidity of the AT 1A R-β-arrestin2 interaction, even when comparing ligands that all evoke a canonical class B pattern of arrestin recruitment.
The rLuc-β-arrestin2-FlAsH BRET signature reflects both changes in the distance/orientation of the fluorophores due to conformational rearrangement, and steric effects generated by arrestin interaction with its receptor and non-receptor binding partners. Although it is not possible to ascribe the rLuc-β-arrestin2-FlAsH BRET signal at a given position to specific conformational shifts or engagement of binding partners, our data clearly demonstrate that ligand-GPCR complexes confer distinctive β-arrestin2 conformations, and that features of the conformational signature are conserved between receptors with similar arrestin binding/signalling characteristics. Moreover, we find that the Δnet BRET at selected positions correlates with downstream arrestin function, for example, class A versus class B trafficking and arrestindependent ERK1/2 activation, suggesting that β-arrestin2-FlAsH BRET probes can predict arrestin function on the basis of the ligandinduced conformational signature. Thus, intramolecular rLucβ-arrestin2-FlAsH BRET probes may aid in identifying the factors that determine arrestin conformation and function, such as ligand 'bias' 8, 9 , GPCR C-tail 'phosphorylation codes' written by different GRKs 28 , and post-translational modifications of arrestin that stabilize or destabilize the complex 29 .
While this work was in progress, we became aware of a complementary study using β-arrestin2-FlAsH fluorescence resonance energy transfer (FRET) sensors 30 . This study confirms the existence of GPCRspecific β-arrestin2 conformations and, with the superior temporal resolution of FRET, provides key insights into the kinetics of receptor binding and arrestin activation.
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to 10 ml of serum free MEM buffered with 10 mM HEPES (pH 7.4). The growth medium was gently aspirated and replaced with 100 μl per well of pre-warmed cAMP reagent medium. Plates were incubated at 37 °C with 5% CO 2 for 1.5 h, then removed from the incubator and incubated at room temperature in the dark for an additional 30 min. Stimulations were performed at room temperature in the FLIPR TETRA using saturating ligand concentrations. Luminescence was recorded every 1 s for 10 reads to establish baseline luminescence, then every 1 s for 50 reads. Thereafter, luminescence was recorded every 2 s for 600 reads. Raw data representing the relationship between time and luminescence for each well following ligand addition was exported to Microsoft Excel for background subtraction and analysis. All responses were normalized to the cAMP luminescence generated in response to 10 μM forskolin. To assay G i -mediated inhibition of cAMP production (α2 2A R and S1P 1 R), cells were pre-incubated with or without agonist for 30 min, then stimulated with 10 μM forskolin. Intermolecular BRET using rLuc-β-arrestin2 and PTH 1 R-YFP. HEK 293 cells were transiently transfected with 1.5 μg of plasmid DNA encoding the C-terminal yellow fluorescent protein (YFP)-tagged PTH 1 R 33 and 0.15 μg of either rLuc-β-arrestin2 or one of the rLuc-β-arrestin2-FlAsH constructs using Fugene HD. Cells were detached 48 h after transfection, collected by centrifugation, resuspended in BRET buffer (1 mM CaCl 2 , 140 mM NaCl, 2.7 mM KCl, 900 μM MgCl 2 , 370 μM NaH 2 PO 4 , 5.5 mM d-glucose, 12 mM NaHCO 3 , 25 mM HEPES (pH 7.4)) and aliquotted into white-wall clear-bottom 96-well plates at a density of 100,000 cells per well. Background and total Venus fluorescence were read on an OptiPlate microplate reader (PerkinElmer) with 485 nm excitation and 525-585 nm emission filters. Cells were stimulated with 0.1 μM PTH(1-34) for 2 min and coelenterazine was then added to a final concentration of 5 μM. Luciferase (440-480 nm) and Venus (525-585 nm) emissions were read to calculate the BRET ratio (emission eYFP/emission Rluc). Net BRET ratio was calculated by background subtracting the BRET ratio measured for vehicle-versus ligand-treated cells in the same experiment. Intramolecular FlAsH BRET using the rLuc-β-arrestin2-FlAsH constructs. HEK293 cells seeded in 6-well plates were co-transfected with 1.5 μg of plasmid DNA encoding the receptor of interest and 0.1 μg of DNA encoding one rLuc-β-arrestin2-FlAsH construct using Fugene HD. Cells were detached 48 h after transfection, collected by centrifugation, and resuspended in 600 μl of Hank's balanced salt solution. TC-FlAsH II In-Cell Tetracystein detection reagent was added at 2.5 μM final concentration and the cells incubated at room temperature for 30 min, after which they were washed using 1× BAL buffer from the TC-FlAsH kit, resuspended in BRET buffer and placed in white-wall clear-bottom 96-well plates at a density of 100,000 cells per well. Background and total TC-FlAsH fluorescence were read on an Optiplate microplate reader (Perkin-Elmer) with 485 nm excitation and 525-585 nm emission filters. Except as noted in the figure legends, all stimulations were carried out at saturating ligand concentration: AngII (0.1 μM), [Arg 8 ]-vasopressin (1 μM), hPTH(1-34) (0.1 μM), isoproterenol (1 μM), phenylephrine (10 μM), S1P (1 μM), SBpA (1 μM), SII (1 μM) SVdF (1 μM), or UK14303 (10 μM). Cells were exposed to agonist for 2-10 min, after which coelenterazine was added at a final concentration of 5 μM. Six consecutive readings of luciferase (440-480 nm) and TC-FlAsH (525-585 nm) emissions were taken, and the BRET ratio (emission eYFP/emission Rluc) calculated using Berthold Technologies Tristar 3 LB 941. The Δnet change in intramolecular BRET ratio for each of the six rLuc-β-arrestin2-FlAsH constructs was calculated by background subtracting the BRET ratio measured for cells in the same experiment stimulated with vehicle only. Confocal microscopy. For determining the pattern of GPCR-arrestin trafficking, HEK293 cells were seeded into collagen-coated 35 mm glass-bottom Petri dishes (MatTek Corporation) and co-transfected with 1.3 μg of plasmid DNA encoding the receptors of interest and 0.7 μg of plasmid encoding green fluorescent protein (GFP)-tagged β-arrestin2 19 using FuGene HD. Forty-eight hours after transfection, cells were serum derived for 4 h, stimulated with a saturating ligand concentration for 8 min, fixed with 4% paraformaldehyde in phosphate buffered saline for 30 min and washed with 4 °C saline. Arrestin distribution was determined by confocal microscopy performed on a Zeiss LSM510 META laser-scanning microscope with 60× objective using 488 nm excitation and 505-530 nm emission wavelengths. Measurement of AT 1A R-β-arrestin2 avidity was performed as previously described 27 . HEK293 cells stably expressing AT 1A R and transfected with β-arrestin2-YFP were stimulated with AngII (1 μM) or analogues (10 μM) for 15 min, after which, endosomes were bleached and fluorescence recovery was monitored every 30 s over a period of 5 min. Immunoblotting. HEK293 FRT/TO β-arrestin1/2 shRNA cells were used to determine the contribution of arrestins to GPCR-stimulated ERK1/2 activation 23, 34 . Cells in 12-well plates were transiently transfected with 1 μg of plasmid cDNA encoding the receptor of interest using FuGENE HD. Twenty-four hours after transfection, downregulation of β-arrestin1/2 expression was induced by 48 h exposure to 1 μM doxycycline. After overnight serum deprivation, cells were stimulated
